<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34416190</PMID><DateCompleted><Year>2022</Year><Month>03</Month><Day>22</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2213-2619</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>12</Issue><PubDate><Year>2021</Year><Month>Dec</Month></PubDate></JournalIssue><Title>The Lancet. Respiratory medicine</Title><ISOAbbreviation>Lancet Respir Med</ISOAbbreviation></Journal><ArticleTitle>Charting a course for the management of long COVID.</ArticleTitle><Pagination><StartPage>1358</StartPage><EndPage>1360</EndPage><MedlinePgn>1358-1360</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S2213-2600(21)00314-3</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2213-2600(21)00314-3</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Beasley</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Medical Research Institute of New Zealand, Wellington 6242, New Zealand. Electronic address: Richard.Beasley@mrinz.ac.nz.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kearns</LastName><ForeName>Nethmi</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Medical Research Institute of New Zealand, Wellington 6242, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hills</LastName><ForeName>Tom</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Medical Research Institute of New Zealand, Wellington 6242, New Zealand; Department of Clinical Immunology, Auckland District Health Board, Auckland, New Zealand.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>08</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Respir Med</MedlineTA><NlmUniqueID>101605555</NlmUniqueID><ISSNLinking>2213-2600</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Lancet Respir Med. 2021 Dec;9(12):1467-1478. doi: 10.1016/S2213-2600(21)00286-1</RefSource><PMID Version="1">34416191</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>RB has received research funding from the Health Research Council of New Zealand through his institution, research funding from AstraZeneca, Genentech, and Fisher &amp; Paykel Healthcare, and honoraria from AstraZeneca, Cipla, Theravance, and Avillion; he is chair of an asthma guidelines group for the Asthma and Respiratory Foundation NZ. NK and TH declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>6</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>6</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>8</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>3</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>8</Month><Day>20</Day><Hour>20</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>8</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34416190</ArticleId><ArticleId IdType="pmc">PMC8372495</ArticleId><ArticleId IdType="doi">10.1016/S2213-2600(21)00314-3</ArticleId><ArticleId IdType="pii">S2213-2600(21)00314-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Huang C, Huang L, Wang Y, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397:220&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature. 2021;594:259&#x2013;264.</Citation><ArticleIdList><ArticleId IdType="pubmed">33887749</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27:601&#x2013;615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Adeloye D, Elneima O, Daines L, et al. The long-term sequelae of COVID-19: an international consensus on research priorities for patients with pre-existing and new-onset airways disease. Lancet Respir Med. 2021 doi: 10.1016/S2213-2600(21)00286-1. published online August 17.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(21)00286-1</ArticleId><ArticleId IdType="pmc">PMC8372501</ArticleId><ArticleId IdType="pubmed">34416191</ArticleId></ArticleIdList></Reference><Reference><Citation>Raman B, Cassar MP, Tunnicliffe EM, et al. Medium-term effects of SARS-CoV-2 infection on multiple vital organs, exercise capacity, cognition, quality of life and mental health, post-hospital discharge. EClinicalMedicine. 2021;31</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7808914</ArticleId><ArticleId IdType="pubmed">33490928</ArticleId></ArticleIdList></Reference><Reference><Citation>Dennis A, Wamil M, Alberts J, et al. Multiorgan impairment in low-risk individuals with post-COVID-19 syndrome: a prospective, community-based study. BMJ Open. 2021;11</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8727683</ArticleId><ArticleId IdType="pubmed">33785495</ArticleId></ArticleIdList></Reference><Reference><Citation>Beasley R, Hills T, Kearns N. Asthma and COVID-19: preconceptions about predisposition. Am J Respir Crit Care Med. 2021;203:799&#x2013;801.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8017587</ArticleId><ArticleId IdType="pubmed">33600744</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramakrishnan S, Nicolau DV, Jr, Langford B, et al. Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respir Med. 2021;9:763&#x2013;772.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8040526</ArticleId><ArticleId IdType="pubmed">33844996</ArticleId></ArticleIdList></Reference><Reference><Citation>Paremoer L, Nandi S, Serag H, Baum F. Covid-19 pandemic and the social determinants of health. BMJ. 2021;372:n129.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7842257</ArticleId><ArticleId IdType="pubmed">33509801</ArticleId></ArticleIdList></Reference><Reference><Citation>Pavord ID, Beasley R, Agusti A, et al. After asthma: redefining airways diseases. Lancet. 2018;391:350&#x2013;400.</Citation><ArticleIdList><ArticleId IdType="pubmed">28911920</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>